Learning Objectives

CAGPO 2018 Conference General Learning Objective

At the completion of this conference, the learner will: 
  • Be familiar with the national legislation regarding MAID and the issue of “conscious objection”;
  • Develop an approach to the diagnosis and treatment of Cancer Associated Thrombosis (CAT), as well as recent changes in the management of CAT;
  • Understand the role of PARP inhibitors in the treatment of metastatic breast and ovarian cancers, as well as management of the major toxicities associated with this class of medication;
  • Be familiar with the role of SBRT in the curative and palliative settings, as well as patient selection and toxicity management;
  • Become familiar with the diagnosis and treatment options available for neuroendocrine tumors, metastatic lung cancer, multiple myeloma and metastatic prostate cancer;
  • Be able to discuss the role of anti-emetics in the management of nausea and vomiting due to systemic therapies;
  • Develop an approach to rotating narcotics;
  • Become familiar with the management of toxicities associated with bone marrow transplantation;
  • Become familiar with the toxicity management of immune-oncology drugs;
  • Understand the role of tyrosine kinase inhibitors (TKIs) in the treatment of advanced renal cell cancer, as well as the management of TKI treatment-related toxicities;
  • Develop an understanding of the role of CDK 4/6 inhibitors in the management of metastatic breast cancer;
  • Be provided with a summary of 3 to 4 practice-changing outcomes from ASCO 2018, as well as three areas of significant change in the standard of care for GI malignancies;
  • Develop an understanding of the role of the substitute decision maker, advanced care planning and goals of care conversations;
  • Become familiar with the presentation of post-traumatic stress disorder in the oncology population, its management and possible prevention strategies.


CAGPO 2018 Talk Specific Learning Objectives

Module 1, hereditary cancer - BRCA
At the completion of this advanced skills workshop the participant will be able to:
  • Identify patterns of cancer diagnoses in families suggestive of possible inherited predisposition syndromes;
  • Understand the basics of cancer risk assessment and the selection of appropriate individuals for genetic testing;
  • Describe the cancer risks associated with mutations in BRCA 1 & 2;
  • Report the evolving literature regarding ovarian cancer screening;
  • Define the incidence of BRCA mutations in a woman with newly diagnosed ovarian cancer;
  • Outline current guidelines for cancer screening and preventative surgery in BRCA carriers;
  • Describe the different cancer rates associated with BRCA 1 & 2 mutations;
  • Differentiate the breast cancer and ovarian cancer risk reduction options for BRCA1 vs BRCA2 carriers;
  • Discuss the benefits and limitations of breast MRI surveillance and prophylactic mastectomy for BRCA carriers;
  • Summarize the evidence regarding prophylactic bilateral salpingo-oophorectomy in BRCA carriers;
  • State the advantages and disadvantages of hysterectomy at the time of prophylactic bilateral salpingo-oophorectomy;
  • Counsel patients regarding decisions about timing of prophylactic surgeries;
  • Review the role of hormone replacement therapy after prophylactic bilateral salpingo-oophorectomy in BRCA carriers with and without breast cancer.

MAID - Where are we now? 
At the conclusion of this presentation, the participants will have a more comprehensive understanding of the national legislation regarding MAID, and the challenges practitioners have encountered since its legalization.  They will acquire an enhanced understanding of “conscious objection” to providing MAID and what are their legal obligations.

CAT 101 
Using a case-based approach, this presentation will provide the learners with an overview of the signs and symptoms of CAT, which patients are at highest risk, and what are the typical symptoms for which we need to educate patients in regards to.  The participant will acquire the knowledge of how to initiate LMWH, when to dose adjust (CrCl, weight-? split dosing, PLT levels), what duration of treatment is most appropriate for a particular patient, as well as how and when to use anti-Xa levels.  Materials from the Thrombosis Canada website will be utilized, in order to educate the learners on what is available for patients and clinicians.

Multiple Myeloma
Learning objectives under development

PARP Inhibitors - their role in the treatment of breast and ovarian cancer 
At the conclusion of this presentation, the learner will have acquired sufficient knowledge to more fully understand the role of PARP inhibitors in the treatment of breast and ovarian cancers. They will understand the mechanism of action of this new class of medication,  when to consider their incorporation into a patient’s treatment plan, how to monitor for toxicities and how to manage the expected and rare side-effects of this class of drugs.
 
Radiation 101 - the role of SBRT
At the completion of this learning activity, participants will be able to evaluate the role of SBRT in potentially curative settings as well as in the palliative setting. They will be able to compare and contrast SBRT to standard radiation.  They will be able to discuss patient eligibility for SBRT, as well as the short and long term toxicities and their management.  They will be able to better comprehend the technical process related to the delivery of SBRT, and discuss whether this modality has changed symptom control and patient survival.

CAT - What is new and practice changing 
At the completion of this presentation, which will build on the presentation CAT 101, the participant will better comprehend new and practice changing developments in the treatment of CAT.  The participants will be able to evaluate the current evidence for the treatment of CAT as it pertains to their oncology patients.
 
NET 
At the conclusion of this learning activity, the participant will have acquired knowledge regarding the updated terminology and classification of NET.  They will more fully understand how NET patients present and what is included in an appropriate diagnostic work up for NET.  The participant will be able to discuss appropriate treatment options ,their availability and efficacy,  as well as the management of symptoms and complications of NET.
 
Metastatic Lung Cancer 
At the completion of this activity, the participant will have acquired sufficient knowledge in order to recommend appropriate pathological testing, as well as be able to describe which tests are presently being used in standard therapy.  They will be knowledgeable regarding the treatment options for first line therapy for patients without treatment altering mutations, as well as for patients with EGFR and ALK mutations.  The learning will be able to describe how age, co-morbidities and ECOG status affect treatment choices.  They will also acquire knowledge regarding which patients will benefit from immune therapies and in which line of treatment these drugs are being utilized.

Bone Marrow Toxicity 
At the conclusion of this learning activity, the participant will comprehend the most common and the most serious toxicities from a BMT and how they are managed.  They will be able to discuss the short and long term risks of BMT.
 
Anti-emetics and rotating narcotics 
Anti-emetics portion
At the conclusion of this presentation, participants will become knowledgeable regarding  the role of anti-emetics in the administration of chemotherapy.   They will acquire the knowledge necessary to understand how to apply the data presented regarding the relevant receptors that are targeted.  They will become familiar with the relevant guidelines for the use of anti-emetics, as well as the potential for drug-drug interactions including which classes of medications one should be concerned, and what actions can be taken to mitigate toxicities.

Rotating narcotics portion
As a result of attending this presentation, the learner will become competent with the rationale for the practice of rotating narcotics,  as well as when, how and why one would choose to alter treatment in this manner.  The learner will be able to discuss the most common pitfalls in rotating narcotics.  The presenter will provide practical suggestions on how to rotate narctoics.
 
Immuno-oncology toxicity management 
At the completion of this presentation, the participant will be more knowledgeable in the toxicities of I-O treatment.  They will comprehend the management of I-O toxicities, including when to dose reduce and when to discontinue therapy.  They will be able to evaluate patient selection for I-O drugs.
 
Metastatic Prostate Cancer 
At the completion of this learning activity, the attendee will become familiar with recent advances in the treatment of metastatic prostate cancer, both in the setting of early metastatic disease and castrate-resistant disease.  The learner will become knowledgeable with the relevant data from the Stampede, Chaarted and Latitude studies.  They will be updated regarding relevant drug toxicities and their management.  They will become competent with the role of bone-modifying agents in the treatment of metastatic disease.

TKIs and RCC
As a result of attending this presentation, the learner will become familiar with new treatment options for patients with advanced renal cell carcinoma, including the efficacy & toxicity profiles of the various treatment options. They will be educated regarding best practices to proactively manage treatment-related toxicities in patients with TKI treatment.
 
Metastatic breast cancer and the CDK 4/6 inhibitors 
At the completion of this presentation, participants will become knowledgeable with the mechanism of action of CDK 4/6 inhibitors, their role in the treatment of metastatic breast cancer, as well as their toxicities and how they are managed.  They will become familiar with patient selection (who is and who isn’t appropriate for this class of drugs).
 
ASCO Update 2018 
As a result of attending this presentation, the learner will become familiar with 3 to 4 practice changing outcomes from ASCO 2018. They will acquire knowledge as to how the data presented can be applied to their patient population.
 
GI Cancer Update 
As a result of attending this presentation, the learner will acquire knowledge regarding 3 major practice-changing developments in the treatment of gastrointestinal malignancies, which have occurred in the last 12 months.  They will become familiar with the published data that has lead to these changes in treatment.  They will understand how these developments are affecting patient care.  They will be comfortable with recognizing and treating the main toxicities associated with these changes in treatment.
 
Talk on Consent
At the completion of this presentation, the learner will understand and appreciate the impact health care consent has on the Substitute Decision Maker(s).  The learner will develop an appreciation for the value of ACP and Goals of Care Conversations in health care decision-making and better understand the role of the health care provider.  This presentation will motivate health care providers to endorse and encourage ACP conversations in an effort to support decision makers (patient or SDM’s).  The presenter will discuss and demonstrate what information is used by substitute decision makers (SDMs) when making treatment decisions.
 
PTSD 
At the conclusion of this presentation, the learner will be able to discuss the incidence and presentation of PTSD and its management in the setting of a cancer diagnosis.  The learning will be able to evaluate management options and potential supportive strategies.  They will be able to evaluate the incidence of chronic PTSD in cancer survivors, and explore what the healthcare team can do differently regarding preventive strategies. This presentation will allow for a mindful consideration of the patients’ perspective.